Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revumenib in relapsed or refractory acute leukemias with KMT2A rearrangement, NPM1 mutation, or related HOX/MEIS-driven alterations
2024-513759-34-00Phase 2Authorised
- Sponsor
- Syndax Pharmaceuticals
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label trial of revumenib in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and mixed phenotype acute leukemia (MPAL), sponsored by Syndax Pharmaceuticals. Primary endpoints: Dose-limiting toxicities, Safety events and 8 more. Planned start May 2022; status: authorised.
02
Drugs
revumenib
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on 2024-513759-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513759-34-00.